Birdwell Kelly A, Ikizler Mine R, Sannella Edith C, Wang Li, Byrne Daniel W, Ikizler T Alp, Wright Peter F
Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN, USA.
Am J Kidney Dis. 2009 Jul;54(1):112-21. doi: 10.1053/j.ajkd.2008.09.023. Epub 2009 Jan 29.
Antibody response to the inactivated influenza vaccine is not well described in kidney transplant recipients administered newer, but commonly used, immunosuppression medications. We hypothesized that kidney transplant recipient participants administered tacrolimus-based regimens would have decreased antibody response compared with healthy controls.
Prospective cohort study of 53 kidney transplant recipients and 106 healthy control participants during the 2006-2007 influenza season. All participants received standard inactivated influenza vaccine.
SETTING & PARTICIPANTS: Kidney transplant recipients administered tacrolimus-based regimens at a single academic medical center and healthy controls.
Presence of kidney transplant.
Proportion of participants achieving seroresponse (4-fold increase in antibody titer) and seroprotection (antibody titer > or = 1:32) 1 month after vaccination.
Antibody titers before and 1 month after vaccination by means of hemagglutinin inhibition assays for influenza types A/H1N1, A/H3N2, and B.
A smaller proportion of the transplantation group compared with the healthy control group developed the primary outcomes of seroresponse or seroprotection for all 3 influenza types at 1 month after vaccination. The response to influenza type A/H3N2 was statistically different; the transplantation group had 69% decreased odds of developing seroresponse (95% confidence interval, 0.16 to 0.62; P = 0.001) and 78% decreased odds of developing seroprotection (95% confidence interval, 0.09 to 0.53; P = 0.001) compared with healthy controls. When participants less than 6 months from the time of transplantation were considered, this group had a significantly decreased response to the vaccine compared with healthy controls.
Decreased sample size, potential for confounders, outcome measure used is the standard but does not give information about vaccine efficacy.
Kidney transplant recipients, especially within 6 months of transplantation, had diminished antibody response to the 2006-2007 inactivated influenza vaccine.
在接受更新但常用的免疫抑制药物治疗的肾移植受者中,对灭活流感疫苗的抗体反应尚未得到充分描述。我们推测,与健康对照相比,接受基于他克莫司方案治疗的肾移植受者的抗体反应会降低。
对2006 - 2007年流感季节的53名肾移植受者和106名健康对照参与者进行前瞻性队列研究。所有参与者均接种标准灭活流感疫苗。
在单一学术医学中心接受基于他克莫司方案治疗的肾移植受者和健康对照。
肾移植的存在。
接种疫苗1个月后达到血清学反应(抗体滴度增加4倍)和血清保护(抗体滴度≥1:32)的参与者比例。
通过对甲型H1N1、甲型H3N2和乙型流感的血凝抑制试验测量接种疫苗前和接种后1个月的抗体滴度。
与健康对照组相比,移植组在接种疫苗1个月后对所有3种流感类型产生血清学反应或血清保护这一主要结果的比例较小。对甲型H3N2流感的反应在统计学上存在差异;与健康对照相比,移植组产生血清学反应的几率降低了69%(95%置信区间,0.16至0.62;P = 0.001),产生血清保护的几率降低了78%(95%置信区间,0.09至0.53;P = 0.001)。当考虑移植时间少于6个月的参与者时,与健康对照相比,该组对疫苗的反应明显降低。
样本量减少、存在混杂因素的可能性、所使用的结果测量方法是标准方法但未提供有关疫苗效力的信息。
肾移植受者,尤其是在移植后6个月内,对2006 - 2007年灭活流感疫苗的抗体反应减弱。